Ocular Therapeutix™ to Provide Corporate Update During 43rd Annual J.P. Morgan Healthcare Conference Presentation

$OCUL
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $OCUL alert in real time by email

Company presentation scheduled on Monday, January 13th at 5:15 PM PT

Ocular to provide enrollment update for SOL-R, Ocular's second registrational trial of AXPAXLI™ in wet AMD, future opportunities for AXPAXLI, and a general corporate overview

BEDFORD, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) --  Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company")), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that the Company will present its strategic outlook for 2025 at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025 at 5:15 PM PT in San Francisco, CA.

Pravin U. Dugel, MD, Ocular's Executive Chairman, President and CEO, will provide an update regarding the enrollment status of SOL-R, the Company's second registrational trial of AXPAXLI™ for the treatment of wet age-related macular degeneration (wet AMD), future opportunities for AXPAXLI, and a general corporate overview.

43rd Annual J.P. Morgan Healthcare Conference Presentation Details

Presentation Date: Monday, January 13, 2025

Presentation Time: 5:15 PM PT

Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO

Location: San Francisco, CA

The live presentation can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page.

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions. AXPAXLI™ (axitinib intravitreal injection, also known as OTX-TKI), Ocular's product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).

Ocular's pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and in its product candidate PAXTRAVA™ (travoprost intracameral injection or OTX-TIC), which is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.

Follow the Company on its website, LinkedIn, or X.

The Ocular Therapeutix logo and DEXTENZA® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

Investors & Media

Ocular Therapeutix, Inc.

Bill Slattery

Vice President, Investor Relations

bslattery@ocutx.com



Primary Logo

Get the next $OCUL alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$OCUL

DatePrice TargetRatingAnalyst
3/18/2025$17.00Outperform
RBC Capital Mkts
3/11/2025$15.00Buy
Needham
10/16/2024Sector Outperform
Scotiabank
6/20/2024$7.00 → $11.00Hold → Buy
TD Cowen
5/31/2024$15.00Overweight
Piper Sandler
2/9/2024$15.00Buy
BofA Securities
4/21/2023$18.00Outperform
Robert W. Baird
8/10/2022$15.00Buy
Berenberg
More analyst ratings

$OCUL
Press Releases

Fastest customizable press release news feed in the world

See more
  • Ocular Therapeutix™ to Participate in Two Investor Conferences in April

    BEDFORD, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a biopharmaceutical company committed to redefining the retina experience, today announced that the Company will participate in two investor conferences in April: 24th Annual Needham Virtual Healthcare ConferencePresentation Date: Monday, April 7, 2025Presentation Time: 3:00 PM ETPresenter: Pravin U. Dugel, MD, Executive Chairman, President and CEOLocation: Virtual Piper Sandler Spring Biopharma SymposiumDate: Thursday, April 17, 2025Ocular Therapeutix to host investor one-on-one meetingsLocation: Boston, MA A live webcast of the Needham presentation can be accessed by visiting the Ocul

    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    BEDFORD, Mass., March 07, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to one newly hired employee. The awards were made as inducements material to the individual's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity awards were granted effective as of March 3, 2025 and consist of (i) a non-statutory stock option to purchase up to 48,000 shares of Ocular's common stock at a per share exercise price equal to the closing pric

    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2024 Results and Business Highlights

    Announces several updates to enhance and accelerate AXPAXLI registrational program in wet AMD, potentially supporting label flexibility of 6-12 months to showcase expected best-in-class durability FDA approves Amendment to SOL-1 Special Protocol Agreement (SPA) to include AXPAXLI re-dosing at Weeks 52 and 76 SOL-1 trial Week 36 primary endpoint data now expected in 1Q 2026 due to requirement for masking until Week 52 to allow for re-dosing Inclusion of re-dosing in SOL-1, along with exceptional retention seen to date in the study, paves way for reduction of SOL-R trial size to 555 subjects (previously 825), potentially accelerating registration timelines Additional updates provided on SO

    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

$OCUL
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$OCUL
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$OCUL
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$OCUL
SEC Filings

See more

$OCUL
Leadership Updates

Live Leadership Updates

See more
  • Ocular Therapeutix® to Host Investor Day on June 13, 2024

    Company to highlight corporate strategy, clinical data, and development plans for AXPAXLI™ in wet AMD and NPDR Event to feature prominent retinal disease experts Baruch D. Kuppermann, MD, PhD (University of California, Irvine) and Dilsher S. Dhoot, MD (California Retina Consultants) In-person event with virtual access to take place on June 13, 2024, at 2:00 PM ET BEDFORD, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD

    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Ocular Therapeutix™ Reports First Quarter 2024 Results

    Recent Leadership Appointments Put Ocular on Track to Become a Leader in Retinal Care Site Activation and Patient Enrollment for AXPAXLI™ SOL-1 Phase 3 wet AMD Trial Progressing with First Subjects Randomized in April 2024 Cash Expected to Support Operations Into 2028, Based on $482.9M March 31, 2024, Cash Balance June 13, 2024, Investor Day to Outline Updated Corporate Strategy BEDFORD, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degenerati

    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders

    Nadia K. Waheed, MD, MPH, Appointed Chief Medical Officer; Peter K. Kaiser, MD, to Become Chief Development Officer; Andrea Gibson, PhD, Named Vice President, Medical Collaborations; and Namrata Saroj, OD, to Become Development Strategy Consultant Dr. Waheed's strong industry track record as a CMO and broad expertise in wet AMD and diabetic retinopathy support advancing the Phase 3 AXPAXLI™ program Dr. Kaiser's vast leadership experience in numerous pivotal trials of approved wet AMD products enhances Ocular's transition to a leading retina care company Dr. Gibson and Dr. Saroj bring deep experience in clinical trial execution through their joint involvement in the development and commerc

    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

$OCUL
Financials

Live finance-specific insights

See more
  • Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2024 Results and Business Highlights

    Announces several updates to enhance and accelerate AXPAXLI registrational program in wet AMD, potentially supporting label flexibility of 6-12 months to showcase expected best-in-class durability FDA approves Amendment to SOL-1 Special Protocol Agreement (SPA) to include AXPAXLI re-dosing at Weeks 52 and 76 SOL-1 trial Week 36 primary endpoint data now expected in 1Q 2026 due to requirement for masking until Week 52 to allow for re-dosing Inclusion of re-dosing in SOL-1, along with exceptional retention seen to date in the study, paves way for reduction of SOL-R trial size to 555 subjects (previously 825), potentially accelerating registration timelines Additional updates provided on SO

    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025

    BEDFORD, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Monday, March 3, 2025, at 8:00 AM ET to discuss recent business progress and financial results for the fourth quarter and full year ended December 31, 2024. Conference Call and Webcast Information: Date: Monday, March 3, 2025, at 8:00 AM ET Participant Dial-In (U.S.): 1 (877) 407-9039 Participant Dial-in (International): 1 (201) 689-8470 Conference ID: 13750940 Webcast Access: Please click here The live and archived webcast can also be acce

    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Ocular Therapeutix™ Reports Third Quarter 2024 Results and Business Highlights

    SOL-1 expected to be fully randomized by YE 2024 with topline data expected in Q4 2025 Active clinical trial sites now enrolling patients directly into SOL-R Cash balance of $427.2M as of September 30, 2024, expected to fund operations into 2028 Ocular to host a Q3 2024 conference call and webcast today, November 14th, at 8:00 AM ET BEDFORD, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company")), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today reported financial results for the

    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

$OCUL
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more